A new dawn: inhaled antibiotics for patients with bronchiectasis

Affiliations

¹ School of Medicine and Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia; Departments of Infectious Diseases and Paediatrics, Gold Coast Health, Gold Coast, QLD, Australia.
² Department of Respiratory and Sleep Medicine, Queensland Children's Hospital, Brisbane, QLD 4101, Australia; Centre for Children's Health Research, Queensland University of Technology, Brisbane, QLD, Australia; Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. Electronic address: anne.chang@menzies.edu.au.

Comment

Keith Grimwood et al. Lancet Respir Med. 2019 Mar.

. 2019 Mar;7(3):188-189.

doi: 10.1016/S2213-2600(18)30456-9. Epub 2019 Jan 15.

¹ School of Medicine and Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia; Departments of Infectious Diseases and Paediatrics, Gold Coast Health, Gold Coast, QLD, Australia.
² Department of Respiratory and Sleep Medicine, Queensland Children's Hospital, Brisbane, QLD 4101, Australia; Centre for Children's Health Research, Queensland University of Technology, Brisbane, QLD, Australia; Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. Electronic address: anne.chang@menzies.edu.au.

No abstract available

Comment on

Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE. Haworth CS, et al. Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15. Lancet Respir Med. 2019. PMID: 30658914 Clinical Trial.